Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

BACKGROUND: Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Langley, Ruth E, Cafferty, Fay H, Alhasso, Abdulla A, Rosen, Stuart D, Sundaram, Subramanian Kanaga, Freeman, Suzanne C, Pollock, Philip, Jinks, Rachel C, Godsland, Ian F, Kockelbergh, Roger, Clarke, Noel W, Kynaston, Howard G, Parmar, Mahesh KB, Abel, Paul D
Format: Artigo
Jezik:Inglês
Izdano: Lancet Pub. Group 2013
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://ncbi.nlm.nih.gov/pubmed/23465742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70025-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki